|

|
|
|
|
| Singapore |
| QIAGEN supports Singapore’s National Precision Medicine programme with sample prep and next-gen sequencing technologies |

QIAGEN has announced that its QIAsprint Connect and QIAseq FX DNA Library Kit will support automated DNA extraction and ...Read more
- 03 November 2026 News
|
|
| Japan |
| Japan's Shionogi transfers generic drug business to Zhejiang Gaozhi Pharma in China |

Japan-based pharma firm Shionogi has announced that Shionogi China, a Shionogi group company in China, has entered into ...Read more
- 03 November 2026 News
|
|
|
|
|
| Korea |
| Merck opens €300 M Asia-Pacific bioprocessing centre in Daejeon, South Korea |

|
Merck, a leading science and technology company, has opened its new Asia-Pacific Bioprocessing Production Centre in Daej...Read more
- 02 November 2026 News
|
|
| India |
| India-based Taisho Ventures receives Rs 7.4 Cr from DBS Foundation to advance active ageing |

|
DBS Foundation has announced SGD 3 million (approximately Rs 22 crore) in funding for four purpose-driven businesses acr...Read more
- 03 November 2026 News
|
|
|
|
|
|
| North America |
| Cambrex breaks ground on $120 M expansion in US for pharma CDMO capabilities |

|
Cambrex, a leading global contract development and manufacturing organisation (CDMO), has marked the groundbreaking of i...Read more
- 03 November 2026 News
|
|
|
|
|
All you want to read on
|

|
|
This email has been sent to you in association with
www.biospectrumasia.com
Tell Us What You Think! Help us improve our newsletters. Send us your feedback!
© Copyright 2026 MM ACTIV. All rights reserved.
To Unsubscribe click here.
Disclaimer : Please remember – by opting-in you are still able to opt-out at any time, by simply replying to this email at digital@mmactiv.com and typing 'unsubscribe' in the 'subject' field of any future emails. We promise only to send emails that we believe you will find interesting, relevant and current. Your data will never be sold or shared with any third party, although we may communicate a message to you from a partner that we are in collaboration with.
|
|
|